Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease

IMPORTANCE: Voretigene neparvovec-rzyl, the first gene therapy approved by the US Food and Drug Administration, was approved for the treatment for RPE65-mediated inherited retinal disease (IRD) in December 2017. This gene therapy is associated with high up-front costs and high efficacy, although of...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Scott, Buessing, Marric, O’Connell, Thomas, Pitluck, Sarah, Ciulla, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646972/
https://www.ncbi.nlm.nih.gov/pubmed/31318398
http://dx.doi.org/10.1001/jamaophthalmol.2019.2512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646972/
https://www.ncbi.nlm.nih.gov/pubmed/31318398
http://dx.doi.org/10.1001/jamaophthalmol.2019.2512

Ejemplares similares